IL218403A0 - Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases - Google Patents
Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseasesInfo
- Publication number
- IL218403A0 IL218403A0 IL218403A IL21840312A IL218403A0 IL 218403 A0 IL218403 A0 IL 218403A0 IL 218403 A IL218403 A IL 218403A IL 21840312 A IL21840312 A IL 21840312A IL 218403 A0 IL218403 A0 IL 218403A0
- Authority
- IL
- Israel
- Prior art keywords
- abt
- solvates
- related diseases
- crystalline forms
- protein related
- Prior art date
Links
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 title 1
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000012453 solvate Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24405109P | 2009-09-20 | 2009-09-20 | |
| PCT/US2010/048949 WO2011034934A1 (en) | 2009-09-20 | 2010-09-15 | Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL218403A0 true IL218403A0 (en) | 2012-04-30 |
Family
ID=43064468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL218403A IL218403A0 (en) | 2009-09-20 | 2012-02-29 | Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US8362014B2 (enExample) |
| EP (1) | EP2477972A1 (enExample) |
| JP (2) | JP2013505249A (enExample) |
| KR (1) | KR20120085781A (enExample) |
| CN (2) | CN102695702A (enExample) |
| AU (1) | AU2010295717B2 (enExample) |
| BR (1) | BR112012006252A2 (enExample) |
| CA (1) | CA2771984A1 (enExample) |
| IL (1) | IL218403A0 (enExample) |
| MX (1) | MX2012003408A (enExample) |
| NZ (1) | NZ598461A (enExample) |
| RU (1) | RU2551376C2 (enExample) |
| TW (1) | TWI488853B (enExample) |
| WO (1) | WO2011034934A1 (enExample) |
| ZA (1) | ZA201202891B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2558434T3 (es) | 2008-11-07 | 2016-02-04 | Amgen Research (Munich) Gmbh | Tratamiento de leucemia linfoblástica aguda |
| HRP20150400T1 (hr) * | 2008-11-07 | 2015-05-08 | Amgen Research (Munich) Gmbh | Lijeäśenje pedijatrijske akutne limfoblastiäśne leukemije |
| US8728516B2 (en) | 2009-04-30 | 2014-05-20 | Abbvie Inc. | Stabilized lipid formulation of apoptosis promoter |
| US20100280031A1 (en) * | 2009-04-30 | 2010-11-04 | Paul David | Lipid formulation of apoptosis promoter |
| US8362013B2 (en) * | 2009-04-30 | 2013-01-29 | Abbvie Inc. | Salt of ABT-263 and solid-state forms thereof |
| TWI532484B (zh) * | 2009-06-08 | 2016-05-11 | 艾伯維有限公司 | 包含凋亡促進劑之固態分散劑 |
| TWI471321B (zh) | 2009-06-08 | 2015-02-01 | 亞培公司 | Ｂｃｌ－２族群抑制劑之口服醫藥劑型 |
| MX2012003408A (es) | 2009-09-20 | 2012-08-03 | Abbott Lab | Formas cristalinas de abt-263 y solvatos para uso para tratar enfermedades relacionadas con la proteina bcl-2. |
| CA2780177A1 (en) * | 2009-12-22 | 2011-06-30 | Abbott Laboratories | Abt-263 capsule |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| CA2900322C (en) * | 2013-02-21 | 2019-03-26 | Pfizer Inc. | Solid forms of the selective cdk4/6 inhibitor compound acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8h-pyrido[2,3-d]pyrimidin-7-one |
| US20160022708A1 (en) | 2013-03-14 | 2016-01-28 | St. Jude Children's Research Hospital | Methods and compositions for the treatment of glutamine-addicted cancers |
| JP2016516808A (ja) * | 2013-04-21 | 2016-06-09 | イェダ リサーチ アンド ディベロップメント カンパニー リミテッドＹｅｄａ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏ．Ｌｔｄ． | Ｂｃｌ−ｘＬおよび／またはＢｃｌ−ｗの活性および／または量を下方制御するための薬剤 |
| CA2939121C (en) | 2014-01-28 | 2020-11-24 | Mayo Foundation For Medical Education And Research | Effective treatment of osteoarthritis, pulmonary disease, ophthalmic disease, and atherosclerosis by removing senescent cells at the site of the disease |
| WO2015116735A1 (en) | 2014-01-28 | 2015-08-06 | Mayo Foundation For Medical Education And Research | Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders |
| US20190269675A1 (en) | 2014-01-28 | 2019-09-05 | Buck Institute for Research and Aging | Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents |
| WO2015157120A1 (en) * | 2014-04-06 | 2015-10-15 | Abraxis Bioscience, Llc | Combination therapy comprising nanoparticles of a taxane and albumin with abt-263 in methods for treating cancer |
| TW201639573A (zh) | 2015-02-03 | 2016-11-16 | 吉李德科學股份有限公司 | 有關治療癌症之合併治療 |
| US20180133212A1 (en) | 2016-11-03 | 2018-05-17 | Gilead Sciences, Inc. | Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer |
| TR201703149A2 (tr) * | 2017-03-01 | 2018-09-21 | Univ Yeditepe | Kemoterapi̇k i̇laç kompozi̇syonu |
| CN108727387B (zh) * | 2018-07-25 | 2021-03-16 | 天津大学 | 依鲁替尼乙酸异丙酯溶剂化合物及其制备方法 |
| CN109053738B (zh) * | 2018-08-29 | 2020-10-16 | 浙江工业大学 | 一种依鲁替尼的溶剂化物及其制备方法 |
| JP7417356B2 (ja) | 2019-01-25 | 2024-01-18 | 株式会社ソニー・インタラクティブエンタテインメント | ロボット制御システム |
| JP2022553820A (ja) | 2019-11-05 | 2022-12-26 | アッヴィ・インコーポレイテッド | 骨髄線維症及びｍｐｎ関連障害をナビトクラクスで処置する際に使用するための投与レジメン |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2713507A (en) | 1948-10-04 | 1955-07-19 | Garlinghouse Brothers | Concrete bucket |
| US7973161B2 (en) | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
| US7075365B1 (en) | 2004-04-22 | 2006-07-11 | Altera Corporation | Configurable clock network for programmable logic device |
| DK1888550T3 (da) * | 2005-05-12 | 2014-09-29 | Abbvie Bahamas Ltd | Apoptosepromotorer |
| MX2009002422A (es) * | 2006-09-05 | 2009-03-20 | Abbott Lab | Inhibidores bcl para tratar exceso de plaquetas. |
| JP4202380B2 (ja) * | 2006-10-17 | 2008-12-24 | シャープ株式会社 | 画像形成装置 |
| CN101939008A (zh) | 2007-12-06 | 2011-01-05 | 雅培制药有限公司 | 用于治疗癌症的abt-263经口组合物 |
| CN101220008B (zh) * | 2008-01-21 | 2011-04-27 | 中国科学院广州生物医药与健康研究院 | 化合物abt-263的合成方法 |
| US8168784B2 (en) * | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
| US8140876B2 (en) * | 2009-01-16 | 2012-03-20 | International Business Machines Corporation | Reducing power consumption of components based on criticality of running tasks independent of scheduling priority in multitask computer |
| US8728516B2 (en) | 2009-04-30 | 2014-05-20 | Abbvie Inc. | Stabilized lipid formulation of apoptosis promoter |
| US20100278921A1 (en) | 2009-04-30 | 2010-11-04 | Fischer Cristina M | Solid oral formulation of abt-263 |
| JP2010259520A (ja) | 2009-04-30 | 2010-11-18 | Motoji Ono | 搬送機構、トレッドミル及びコンベア |
| US20100297194A1 (en) | 2009-04-30 | 2010-11-25 | Nathaniel Catron | Formulation for oral administration of apoptosis promoter |
| US8362013B2 (en) * | 2009-04-30 | 2013-01-29 | Abbvie Inc. | Salt of ABT-263 and solid-state forms thereof |
| US20110047552A1 (en) * | 2009-05-11 | 2011-02-24 | Raytheon Bbn Technologies Corp. | Energy-aware process environment scheduler |
| US8291422B2 (en) * | 2009-05-11 | 2012-10-16 | Bbn Technologies Corp. | Energy-aware computing environment scheduler |
| MX2012003408A (es) | 2009-09-20 | 2012-08-03 | Abbott Lab | Formas cristalinas de abt-263 y solvatos para uso para tratar enfermedades relacionadas con la proteina bcl-2. |
| CN101798292A (zh) | 2010-03-29 | 2010-08-11 | 无锡好芳德药业有限公司 | ABT-263衍生的新型Bcl-2蛋白抑制剂的制备 |
-
2010
- 2010-09-15 MX MX2012003408A patent/MX2012003408A/es unknown
- 2010-09-15 US US12/882,576 patent/US8362014B2/en active Active
- 2010-09-15 BR BR112012006252A patent/BR112012006252A2/pt not_active IP Right Cessation
- 2010-09-15 CN CN2010800417753A patent/CN102695702A/zh active Pending
- 2010-09-15 AU AU2010295717A patent/AU2010295717B2/en not_active Ceased
- 2010-09-15 CA CA2771984A patent/CA2771984A1/en not_active Abandoned
- 2010-09-15 EP EP10757361A patent/EP2477972A1/en not_active Withdrawn
- 2010-09-15 CN CN201610194338.4A patent/CN105820138A/zh active Pending
- 2010-09-15 NZ NZ598461A patent/NZ598461A/en not_active IP Right Cessation
- 2010-09-15 KR KR1020127010148A patent/KR20120085781A/ko not_active Ceased
- 2010-09-15 RU RU2012115851/04A patent/RU2551376C2/ru not_active IP Right Cessation
- 2010-09-15 WO PCT/US2010/048949 patent/WO2011034934A1/en not_active Ceased
- 2010-09-15 JP JP2012529878A patent/JP2013505249A/ja active Pending
- 2010-09-20 TW TW099131885A patent/TWI488853B/zh not_active IP Right Cessation
-
2011
- 2011-07-28 US US13/193,013 patent/US8513243B2/en not_active Expired - Fee Related
-
2012
- 2012-02-29 IL IL218403A patent/IL218403A0/en unknown
- 2012-04-19 ZA ZA2012/02891A patent/ZA201202891B/en unknown
-
2015
- 2015-07-17 JP JP2015142670A patent/JP2015232006A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010295717B2 (en) | 2014-09-11 |
| NZ598461A (en) | 2013-12-20 |
| AU2010295717A1 (en) | 2012-03-22 |
| US20110294811A1 (en) | 2011-12-01 |
| TW201116526A (en) | 2011-05-16 |
| US20110071151A1 (en) | 2011-03-24 |
| US8513243B2 (en) | 2013-08-20 |
| KR20120085781A (ko) | 2012-08-01 |
| RU2551376C2 (ru) | 2015-05-20 |
| MX2012003408A (es) | 2012-08-03 |
| CN102695702A (zh) | 2012-09-26 |
| CA2771984A1 (en) | 2011-03-24 |
| JP2013505249A (ja) | 2013-02-14 |
| WO2011034934A1 (en) | 2011-03-24 |
| CN105820138A (zh) | 2016-08-03 |
| JP2015232006A (ja) | 2015-12-24 |
| ZA201202891B (en) | 2013-09-25 |
| TWI488853B (zh) | 2015-06-21 |
| US8362014B2 (en) | 2013-01-29 |
| RU2012115851A (ru) | 2013-10-27 |
| BR112012006252A2 (pt) | 2017-05-23 |
| EP2477972A1 (en) | 2012-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201202891B (en) | Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases | |
| IL217540A (en) | An oral preparation for use in oral disinfection or in the treatment of oral diseases | |
| ZA200903860B (en) | Treatment of PRDC in pigs | |
| EP2521724A4 (en) | ACTIVE AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES | |
| EP2200549A4 (en) | METHODS AND DEVICES FOR INTEGRATED CATARACT SURGERY | |
| SMT202300433T1 (it) | Peptide per l'uso nella prevenzione o nel trattamento della degenerazione maculare | |
| SI2440550T1 (sl) | Indolamidni derivati in povezane spojine za uporabo pri zdravljenju neurodegenerativnih bolezni | |
| ZA201106545B (en) | Apparatus for bone restoration of the spine and methods of use | |
| EP2271218A4 (en) | USE AND COMPOSITION FOR THE TREATMENT OF DEMENTIA | |
| IL210511A0 (en) | Device for sterilizing water and use of same | |
| SG10201403758SA (en) | Methods and compositions for use in cellular therapies | |
| EP2429584A4 (en) | TREATMENT PROCEDURE AND COMPOSITIONS | |
| IL206549A (en) | A device for treating and using tinnitus | |
| IL220661A0 (en) | Beta-carbolines for use in the treatment of hearing loss and vertigo | |
| EP2205236A4 (en) | NEW MEANS FOR THE TREATMENT OF DISEASES AND FUNCTIONAL DISORDERS | |
| IL206173A0 (en) | 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases | |
| ZA200900489B (en) | Apparatus and methods for skin treatment | |
| IL202307A0 (en) | Multikinase inhibitors for use in the treatment of cancer | |
| GB0724238D0 (en) | Apparatus for use in the care of animals | |
| GB0619816D0 (en) | Novel interferon-alpha constructs for use in the treatment of cancer | |
| EP2421552B8 (en) | Collagen v for use in the treatment of asthma | |
| EP2462131A4 (en) | COMPOSITIONS AND METHODS FOR TREATING DISEASES ASSOCIATED WITH BETA-AMYLOID | |
| HK1173725A (en) | Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases | |
| IL220241A0 (en) | Use of transferrin in treatment of beta-thalassemias | |
| ZA201206853B (en) | Composition for use in water treatment |